VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
178.12
+1.98 (+1.12%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close176.14
Open177.01
Bid178.22 x 800
Ask178.23 x 1200
Day's Range176.00 - 179.52
52 Week Range151.80 - 195.81
Volume1,177,955
Avg. Volume1,148,780
Market Cap45.783B
Beta (3Y Monthly)1.05
PE Ratio (TTM)20.91
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • 3 Big Biotech Stocks Worth Adding to Your Portfolio Now
    Zacks

    3 Big Biotech Stocks Worth Adding to Your Portfolio Now

    We highlight a few key biotech stocks that surpass the sector so far in 2019 and are likely to witness a winning run in the near term.

  • The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial
    Zacks

    The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial

    The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial

  • Top Stock Reports for Celgene, Sinopec & HSBC
    Zacks

    Top Stock Reports for Celgene, Sinopec & HSBC

    Top Stock Reports for Celgene, Sinopec & HSBC

  • How Much Are Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Insiders Taking Off The Table?
    Simply Wall St.

    How Much Are Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Insiders Taking Off The Table?

    We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...

  • Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland
    Zacks

    Vertex Gains Reimbursement for Orkambi & Symkevi in Scotland

    Vertex (VRTX) secures reimbursement nods in Scotland for its cystic fibrosis drugs Orkambi and Symkevi.

  • Vertex strikes deal to sell cystic fibrosis drugs in Scotland, but British debate continues
    American City Business Journals

    Vertex strikes deal to sell cystic fibrosis drugs in Scotland, but British debate continues

    While Vertex’s drug pricing battle with British regulators continues, it has made advances abroad, signing a deal this week to make two of its cystic fibrosis drugs available in Scotland.

  • Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?
    Zacks

    Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?

    Is (VRTX) Outperforming Other Medical Stocks This Year?

  • Don’t Blink or You’ll Miss Vertex’s Next Move, And It’s Bound to Be a Good One
    Motley Fool

    Don’t Blink or You’ll Miss Vertex’s Next Move, And It’s Bound to Be a Good One

    The pharma and biotech industries are high risk. But Vertex Pharmaceuticals is boldly soldiering on and wisely investing where it has a competitive advantage.

  • GuruFocus.com

    Wall Street Green on Wednesday

    Navistar jumps on strong quarterly results Continue reading...

  • Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M
    Zacks

    Vertex (VRTX) Inks All-Cash Deal to Acquire Semma for $950M

    Vertex (VRTX) inks an all-cash deal to buy privately-held Semma Therapeutic. The acquisition will add pre-clinical type I diabetes candidates to its pipeline.

  • Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More
    Zacks

    Biotech Stock Roundup: REGN Wins Against AMGN, VRTX to Acquire Semma & More

    Key highlights of the past week include litigation updates, acquisitions, and other regulatory and pipeline updates.

  • Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff
    Motley Fool

    Vertex Pharmaceuticals' $950 Million Bet on Curing Type 1 Diabetes Could Have an Astronomical Payoff

    The biotech just announced a potentially game-changing acquisition.

  • Barrons.com

    Buy Vertex Pharmaceuticals Stock Because of Its ‘Emerging Pipeline’

    Goldman Sachs upgraded Vertex Pharmaceuticals on Monday, adding the Buy-rated stock to the research department’s Americas Conviction List.

  • Benzinga

    Vertex To Acquire Diabetes Treatment Company Semma Therapeutics For $950M

    Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX ) will acquire Semma Therapeutics , a privately held biotechnology company that uses of stem cell-derived human islets as a potentially curative treatment ...

  • Vertex snaps up Cambridge diabetes startup Semma for $950M
    American City Business Journals

    Vertex snaps up Cambridge diabetes startup Semma for $950M

    Vertex Pharmaceuticals has struck a deal to acquire local diabetes-focused startup Semma Therapeutics, marking another substantial pivot for the company as CEO Jeff Leiden's tenure comes to a close.

  • Reuters

    UPDATE 1-Vertex to buy cell therapy developer Semma for $950 mln

    Vertex Pharmaceuticals Inc said on Tuesday it would buy privately held Semma Therapeutics for $950 million in cash with an aim to develop potentially curative stem-cell based treatments for diabetes. The deal represents Vertex's foray into a new treatment space, as the company typically develops treatments for cystic fibrosis, an inherited disorder that causes damage to the lung and digestive system. "We see a substantial opportunity to transform the treatment paradigm for type 1 diabetes, a specialty disease cared for by endocrinologists," said Vertex's Chief Executive Officer Jeffrey Leiden.

  • Looking For Growth? Take A Look At These Biotechnology Stocks
    Investor's Business Daily

    Looking For Growth? Take A Look At These Biotechnology Stocks

    The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth.

  • 3 Healthcare Stocks That Have a Killer Advantage
    Motley Fool

    3 Healthcare Stocks That Have a Killer Advantage

    These healthcare winners have such strong competitive advantages that their theme song could be MC Hammer's "U Can't Touch This."

  • Benzinga

    Barron's Picks And Pans: Activision Blizzard, Best Buy, Coca-Cola, Microsoft And More

    This weekend's Barron's cover story offers a look at biotechnology companies developing cutting-edge drugs. Other featured articles discuss the outlook for stocks and bonds in the fall and how to play ...

  • Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know
    Zacks

    Vertex Pharmaceuticals (VRTX) Gains But Lags Market: What You Should Know

    Vertex Pharmaceuticals (VRTX) closed at $178.98 in the latest trading session, marking a +0.36% move from the prior day.

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Fool

    3 Top Biotech Stocks to Buy Right Now

    Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.

  • Moving Average Crossover Alert: Vertex Pharmaceuticals
    Zacks

    Moving Average Crossover Alert: Vertex Pharmaceuticals

    Vertex Pharmaceuticals Incorporated (VRTX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

  • 3 Big Stock Charts for Tuesday: TechnipFMC PLC, Vertex Pharmaceuticals and Constellation Brands
    InvestorPlace

    3 Big Stock Charts for Tuesday: TechnipFMC PLC, Vertex Pharmaceuticals and Constellation Brands

    Stocks bounced back from Friday's misery to start the new trading week on renewed hopes for some sort of trade deal with China. But, given the scope of Friday's meltdown, a bounce was nearly inevitable. Even with Monday's gain of 1.1%, the S&P 500 is still down 1.5% from Thursday's close.Source: Shutterstock Teva Pharmaceutical (NYSE:TEVA) led the way with its 5.2% gain during regular-hours action, followed by more than a 2% pop in after-hours trading on a small wave of encouraging news that emerged for the struggling company last week. Roku (NASDAQ:ROKU) wasn't far behind though, rallying nearly 4% as investors continue to chase its move into record-high territory.Holding the market back more than any other name was Philip Morris (NYSE:PM), down more than 4% on rumors it may merge with Altria Group (NYSE:MO).InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 10 Companies Using AI to Grow As for names worth a look headed into today's action, take a look at the stock charts of TechnipFMC PLC (NYSE:FTI), Constellation Brands (NYSE:STZ) and Vertex Pharmaceuticals (NASDAQ:VRTX). Here's why. Constellation Brands (STZ)Constellation Brands shares, like most other stocks, snapped out of their late-2018 funk with a clear rebound. The effort since April, however, has been choppy at best and ineffective at worst. The end result is the formation of a converging wedge pattern that's still got STZ stock contained.There's solid bullish work still being done within that containment though, that's worth noting because it could be setting up a breakout thrust. With four months' worth of pent-up energy ready to unleash, that move could be a very tradeworthy one. Click to Enlarge * The wedge is plotted on both stock charts, with the upper boundary marked by a yellow line and the lower boundary marked by a blue line. Constellation Brands is one good day away from breaking above the ceiling. * Another technical ceiling has also taken shape since last month. STZ shares have peaked twice around $206, marked in red on both stock charts. * We've not seen it happen yet, but for any breakout to be truly healthy, support has to start materializing at one or more of the moving average lines. Most are right around $196 now. Vertex Pharmaceuticals (VRTX)The past several months haven't been easy ones for Vertex Pharmaceuticals shareholders. The stock has gone nowhere, but it has still been sea-sickeningly volatile. A key support as well as a key resistance line have both been breached, but in both cases, it's only temporarily.These past few months haven't been pointless though. They've helped define how and where traders are drawing their mental lines in the sand. And, with one more good "oomph" to get VRTX shares above the ceiling -- the stock couldn't hold above earlier in the month -- shares could finally breakout out of their rut. * 7 5G Stocks to Connect Your Portfolio To Click to Enlarge * It's plotted on both stock charts. That is, Vertex shares have been squeezed toward the tip of a converging wedge shape that materialized at the beginning of this year. * The upper boundary, marked in yellow, failed to keep the rally effort in check earlier this month, though VRTX fell back under it last week. A second wind, however, could get and keep it above that ceiling. * It would be easy to miss given the sheer number of moving average crosses since late last year, but as of last week, we're now in the shadow of a so-called golden cross, where the purple 50-day line is above the white 200-day line. TechnipFMC PLC (FTI)Even though it's an S&P 500 component, most investors have likely never heard of TechnipFMC PLC. Don't let its obscurity or relatively small size mislead you though. Even with a market cap of a modest $10 billion, the oil and gas technology stock can move and shake things up within the industry. And, like most other energy names, FTI was hit pretty hard in the last quarter of last year.Things have been different this year though … not necessarily for the better, but moving in that direction. Even though the bulk of Monday's intraday gain was given back, the bulls once again tipped their hand to say they're increasingly interested in owning this name. * Click to EnlargeOnce again, the stock in question is framed by a yellow resistance line and blue support line on both stock charts. But, this time, those lines are part of a diverging wedge, rather than converging one. * At the very least, the kiss of the lower boundary of the trading range in mid-August sets the stage for a move to the upper boundary, to repeat the pattern that has been in place since early this year. * As was the case with Constellation Brands, the key from here will be finding support at the moving average lines. None appeared to be support on Monday, though it's likely the bulls will try again this week.As of this writing, James Brumley did not hold a position in any of the aforementioned securities. You can learn more about him at his website jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Companies Using AI to Grow * The 10 Biggest Winners From Second-Quarter Earnings * 7 Marijuana Penny Stocks to Consider for Those Who Can Handle Risk The post 3 Big Stock Charts for Tuesday: TechnipFMC PLC, Vertex Pharmaceuticals and Constellation Brands appeared first on InvestorPlace.

  • Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?
    Zacks

    Has Vertex Pharmaceuticals (VRTX) Outpaced Other Medical Stocks This Year?

    Is (VRTX) Outperforming Other Medical Stocks This Year?